rev: August 19, 2004
HOME (index page)
Return (alphabetical antibody page)
ANTIBODIES
(anti-Human and others as indicated)
RDI Divison of researchd Industries Intl offers a wide line of antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.
Cat#RDI-PRO651108 $345.00/vial 5ml TCS formulation
cat#RDI-PRO610108 $410.00/1vial $375/vial 10+ 50ug (lyophilized) with 0.5%BSA & 0.09% NaN3
Clone AU1
Category Mouse monoclonal
Immunoglobulin Class IgG1
Form/Purification Hybridoma culture supernatant
Antigen
Asymetric unit membrane (AUM) preparation from bovine urinary bladder
Description/Specificity Mab AU1 reacts specifically with uroplakin III present in the superficial cell layer of the urothelium. Together with uroplakins UP 1A, UP 1b, and UP II, uroplakin III contributes in constituting the asymetrical unti membrane of the plaques of urothelial glycoprotein (47kD) and has been shown to be a specific marker of terminal urothelial differentiation (Wu et al., 1983, 1994).
Antibody AU1 strongly stains the urothelial surface membrane in paraffin sections of human renal pelvis, ureter, bladder, and uretha. About 60% of human transitional cell carcinomas (including metastases) maintain focal (sometimes very limited) expression of uroplakin III. Until know, no uroplakin staining was found in any non-urothelial carcinoma (Moll et al 1995). Uroplakin III may thus serve as a specific urothelial differentiaition marker in cases of metastatic carcinomas with unclear primary tumor
Antigen Recognized in Species (tested so far) Human, bovine, rat (canine reported)
Application Suitable for
· immunohistochemistry on paraffin-embedded tissue (NOT ON FROZEN SECTIONS)
· immunoblotting (Western)
Working Dilution Ready-to-use for immunohistochemistry (cat#RDI-PRO651108)
1:10 for histochemistry (cat#RDI-PRO610108)
Incubation Time 1 h at RT for immunohistochemistry
Storage At 2-8°C
Quantity 5 ml (contains 0.09% NaN3) cat#RDI-PRO651108
50ug in 1ml PBS with 0.5%BSA & 0.1% NaN3 cat#RDI-PRO610108
References
1. Wu XR, Sun TT:Molecular cloning of a 47kD tissue specific and
differentiation-dependent urothelial cell surface glycoprotein. J. Cell Sci.
106, 31-43 (1993)
2. Wu XR, Lin JH, Waltz T, Haner M, Yu J, Aebi U, Sun TT:Mammalian uroplakins:a
group of highly conserved urothelial differentiation- releated membrane proteins.
J. Biol Chem 269:13716-13724 (1994)
3. Moll R, Wu XR, Lin JH, Sun TT: Uroplakins, specific membrane proteins
of urothelial umbrella cells, as histological markers of metastatic transitional
cell carcinomas. Am J Pathol. 147, 1383-1397 (1995)
4. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemisal marker for primary and metastatic urothelial carcinomas. Am J, Clin Pathol 2000;113:683-687
ABSTRACT:-Uroplakins are specific differentiation products of terminally differentiated superficial urothelial cells, The authors tested the value of a new commerically available monoclonal antibody agaianst uroplakin III (clone AU1) as a paraffin-reactive immunohistochemical marker for primary and metastatic urothelial carcinomas. The study cases included 67 urothelial carcinomas of the urinary tract (35 primary tumors, 32 metastases) and 318 nonurothelial carcinomas, as well as five benign Brenner tumors and two transitional cell carcinomas of the ovaries. Uroplakin III was detected in 21 (60 precent) of the primary urothelial carcinomas and 17 (53 percent) of the metastases, resulting in an overall sensitivity of 0.57. The studied Brenner tumors also were immunoreactive for uorplakin III. All other studied carcinomas were consistently uroplakin III negative( specificity, 1.0). Researchers found the new monoclonal anitbody clone AU1 against uroplakin III to be highly specific paraffin-reactive immunohistochemical markeer for urothelial tumors with a moderate sensitiivty for identifying primary and metastatic urothelial carcinomas.
5. Hu P et al, Ablation of Uroplakin III gene results in small urothelial plaques, urothelial leakag, and vesicoureteral reflux, J. Cell Biol 151, 961-971(2000)
6. Riedel I et al, Brenner Tumors but not transitional cell carcinomas of the ovary show urothelial differentiation:Immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch 438,181-191 (2001)
7. Liang F-X et al, Organziation of uroplakin subunits:transmembrane topology, pair formation and plaque composition. Biochem J. 355, 13-18 (2001)
8. Romih R et al: Uroplakins and cytokeratins in the regenerating rat urothelium after sodium saccharin treatment Histochem Cell Biol 109:263-269 (1998)
For In Vitro Research Use Only
San Jose, 95123 CA Snell ave 658
USA
or 408-780-0908
EMAIL:margaret@cellular-research.com
Return (alphabetical antibody list)
Ordering terms